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This work  aimed  to  design  dapsone  (DAP)  amorphous  Polymeric  Dispersions  (PD)  using  design  of  exper-
iments  (DoE)  and  response  surface  methodology  (RSM)  as optimization  tools  in  order  to  tailor  the
biopharmaceutical  properties  toward  its  oral  delivery.  A  two-factor,  three-level  (32) statistical  design
was  implemented  to  study  the inﬂuence  of  input  variables  (amount  of  PVP  K30 and  Pluronic  F68)  on
the  equilibrium  solubility  of DAP  of the  physical  mixture  (PM),  kneaded  (KN)  and  freeze  dried  (FD)  PDs.
Through  the  analysis,  it was  found  that equilibrium  solubility  of  DAP  was  improved  with  increasing  of
PVP K30,  mainly  for FD PDs,  but  decreased  with  increasing  Pluronic  F68  concentration.  XRD  and  FTIR
spectrum  revealed  the amorphous  characteristic  of  FD  PDs and  SEM  conﬁrmed  the  homogeneity  of  thereeze drying
esign of experiments
uality by design
system  leading  to enhanced  surface  area  and  consequent  dissolution  rate. The  in  vitro  dissolution  rate
of PDs  was  signiﬁcantly  faster  compared  to DAP  and  PM,  and  all the  similarity  factors  (f2)  were below
50,  demonstrating  the  differences  on  the dissolution  proﬁles.  The  results  established  the  effectiveness  of
PDs for  improvement  of  dissolution  and solubility  of  DAP  and  the  success  in the implementation  of  DoE
and  RSM  as QbD  tools  in  the design  of  PDs.. Introduction
Leprosy is a chronic infectious disease that continues to be
 serious public health problem in several developing countries,
aused by Mycobacterium leprae (M.  Leprae)  [1]. It is a slowly grow-
ng intracellular bacillus, transmitted from an infected person to
thers via their nasal secretions [2]. The disease affects periph-
ral nerves, especially Schwann cells, as well as skin and multiple
nternal organs such as the reticulo-endothelial system, bones and
oints, mucous membranes, eyes, testes, muscles, and adrenals [3].
ts clinical manifestations are related to the level of cell-mediated
mmunity of individual patients [1,4]. The multidrug therapy con-
ists in combinations of dapsone (DAP), rifampicin, and clofazimine
∗ Corresponding author at: Faculty of Pharmacy – University of Porto, Rua Jorge
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to treat multibacillary leprosy (MB), while DAP in combination with
rifampicin is usually used to treat paucibacillary (PB) leprosy [1].
Dapsone (4,4′-diamino-diphenylsulfone, DAP) is a bacteriostatic
drug that acts by competitive inhibition of the enzyme dihydrofo-
late synthetase and dihydrofolate reductase, key enzymes in the
folate biosynthesis pathway in M.  leprae [1,5]. Despite its thera-
peutic potential, DAP is classiﬁed as a class II compound according
to the Biopharmaceutics Classiﬁcation System (BCS) [6], and its low
solubility was  found to result in a low therapeutic index and high
microbial resistance [7]. Several approaches have been attempted
in order to improve DAP water solubility, such as encapsulation
into nanoparticles [8], inclusion complexes with cyclodextrins [9],
nanoemulsion [10,11] and co-crystals [7]. However, these strate-
gies are often confronted with few practical limitations and the
desired bioavailability enhancement may  not always be achieved
[12]. In this framework, solid dispersion system is one of the
promising methods to improve the aqueous solubility of poorly
soluble drugs, especially for oral solid dosage forms.
In these formulations, the drug dissolution rate may  be
improved by reducing the drug particle size to almost a molecular
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data was performed by RSM. The polynomial model given by Eq.
(1) was  applied as the response function:
Y = A0 + A1X1 + A2X2 + A3X1X2 + A4X12 + A5X22 (1)
Table 1
Independent variables and their corresponding levels of PD preparations.
Variables LevelsL.L. Chaves et al. / International Journal of
evel and by modifying the drug crystallinity to generate a com-
letely or partially amorphous state, increasing their saturation
olubility in gastrointestinal ﬂuids [13,14].
In the last few years, the International Conference on Harmo-
ization Q8 guidelines, described the concept of quality by design
QbD) [15], which is getting great attention in pharmaceutical for-
ulation development, focusing on the science of production, to
onstruct a systematically quality in the ﬁnal pharmaceutical prod-
ct [12,16]. It is widely known that formulation optimization can be
mplemented by the use of a combination of analytical approaches,
uch as design of experiments (DoE), response surface methodol-
gy (RSM), and optimization [17]. DoE is a structural and organized
rocedure for determination of critical factors that could affect
he process or product in order to ensure their reliability and
obustness [16,18]. Likewise, RSM is applied to describe correla-
ions between causal factors and response variables, enabling to
mprove understanding of the inﬂuence of different excipients and
heir interactions as well as predicting optimized formulations with
he desired proﬁle [18,19].
Although the QbD concept seems promising, currently, few
orks have been developed in the ﬁeld of solid dispersions on the
mportance of process and formulation factors [16,18,20,21].
The present study aimed to develop DAP amorphous Polymeric
ispersions (PDs) by using DoE and RSM as optimization tools. For
his purpose, a suitable carrier was chosen from an initial poly-
er  screening, and the improvement on the equilibrium solubility
as chosen as critical parameter. Additionally, it was  determined
he inﬂuence of PDs process in the selected polymer and also the
nﬂuence of a third component on the drug equilibrium solubility.
t was used two types of solvent evaporation methods (kneading
nd freeze-drying), due to their simplicity and potential for scale-
p, to manufacture PDs. The PDs were subsequently characterized
egarding their crystallinity, morphology and molecular interac-
ions. In vitro drug dissolution study was then performed with the
ormulations.
. Material and methods
.1. Material
DAP was purchased from CHEMOS GmbH (Regenstauf,
ermany). Polyethyleneglycols (PEG 1500, PEG 4000, PEG 8000
nd PEG 20000), low molecular weight chitosan and Pluronic®
-68 were purchased from Sigma–Aldrich (St. Louis, USA); hydrox-
propyl methylcellulose (HPMC; METHOCELTM E5LV) was  obtained
rom Colorcon Limited, UK. Polyvinylpyrrolidone (PVP K30) was
btained from Fluka (Buchs, Switzerland). Compritol® ATO 888
nd Gelucire® 44/14 were gifted from Gatefossé (Saint-Priest,
rance) and inulin was kindly provided by Sensus (Roosendaal, the
etherlands). Ethanol (VWR chemicals), acetonitrile (VWR chemi-
als) and ultra-pure water (MilliQ) were used in preparation of the
olid dispersions.
.2. Methods
.2.1. Equilibrium solubility of DAP at different pH aqueous
olutions
Solubility studies of DAP were performed according to the shake
ask method [22]. An excess amount of drug (±20 mg)  was weighed
n test tubes containing 10 mL  of ultra-pure water, or selected
uffer solutions, namely hydrochloric acid buffer pH 1.2, acetate
uffer pH 4.5 and phosphate buffer pH 6.8 and 7.4 [23]. The sam-
les were mechanically stirred in a thermostatic water bath at
7 ± 1 ◦C, for simulating physiological conditions [22], or 25 ± 1 ◦C
or 48 h. Subsequently, the suspensions were ﬁltered using paperical Macromolecules 81 (2015) 662–671 663
ﬁlters (Whatman no. 5), and quantiﬁed by spectrophotometry at
291 nm.  All the experiments were conducted in triplicates.
2.2.2. Screening of different polymeric carrier
The effect of different carriers on the solubility of DAP was
studied by formulating physical mixtures (PM) of DAP and several
hydrophilic and hydrophobic carriers (PEG 1500, PEG 4000, PEG
8000, PEG 20000, Pluronic F68, chitosan, inulin, Gelucire®44/14,
Compritiol ATO 888; HPMC and PVP K30) at the ratio 1:1 and
1:5 (w/w). The equilibrium solubility was the parameter chosen
(quality attribute) for the selection of the suitable carrier for the
improvement of DAP solubility, which were performed similarly to
the equilibrium solubility of DAP in ultra-pure water, at 37 ± 1 ◦C,
for 48 h.
2.2.3. Preparation of physical mixture
PM were prepared by weighing known amounts of DAP and
the respective amounts of carriers, respecting the ratios studied
which were merely mixed vigorously with a vortex during 5 min
for complete homogenization.
2.2.4. Preparation of solid dispersions
2.2.4.1. Kneading method. Kneaded (KN) PDs were prepared with
DAP: polymer ratios of 1:1, 1:3 and 1:5 (w/w). Accurately weighed
quantity of polymer and drug were mixed with a mortar and a pes-
tle, with sufﬁciently amount of a hydro-alcoholic solution (50:50
water/ethanol), which was dripped while the mixture was kneaded
until the obtaining of a smooth and homogeneous mass. Finally the
mass was  dried in an oven at 60 ◦C for 2 h and then passed through
a #100 sieve. The PD were then stored in desiccator.
2.2.4.2. Freeze-drying method. Firstly, known amounts of DAP and
PVP K30 were dissolved in acetonitrile and water respectively,
respecting the ratios studied (1:1, 1:3 and 1:5, w/w). The solutions
were maintained in magnetic stirring during 48 h, for the complete
solvent evaporation and better interaction drug-polymer. The ﬁnal
solutions were then frozen at −84 ◦C for 24 h. The samples were
freeze-dried (Lyoquest ECO, Telstar) using a condenser tempera-
ture of −65 ◦C and pressure of 0.5 mbar, during 48 h, in order to
obtain a dry cake. The samples were stored in desiccator for a com-
plete drying.
2.2.5. Design of experiments
The experiments were carried out following a full factorial
design to optimize and evaluate the effect of material attributes
on the equilibrium solubility of DAP PDs obtained by two differ-
ent methods (kneading and freeze-drying) and the respective PM.
A two  factor, three level (32) design were performed in order to
explore response surfaces and constructing second-order polyno-
mial models with STATISTICA 10 (Statsoft Inc., USA). The factors
studied were the amount of polymer and the inﬂuence of a surfac-
tant as a third component in the formulation. The levels and factors
are given in Table 1. The response adopted was the equilibrium sol-
ubility after 48 h, at 25 ◦C. The ANOVA analysis of the experimental−1 (mg) 0 (mg) +1 (mg)
X1 200 600 1000
X2 0 8 20
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DAP. Hydrophilic systems, i.e., polymeric matrices, are the most
used to develop PDs [30]. Among the hydrophilic polymers tested
(PEGs, HPMC and PVP K30), only the PVP K30 was found to sig-
niﬁcantly inﬂuence DAP solubility, and this increment seems to be64 L.L. Chaves et al. / International Journal of
here Y: dependent variable (equilibrium solubility); X1: amount
f polymer (mg) PVP K30; X2: amount of surfactant (mg) Pluronic
68; X1X2: represent the interaction term; Xi2: quadratic terms;
nd Ai: polynomial coefﬁcients.
The effects of the factors were considered signiﬁcant when
he ANOVA results indicated a signiﬁcance level higher than 5%
p < 0.05).
.2.6. Solid dispersions characterization
.2.6.1. X-ray diffraction. The X-ray power diffraction (XRD) data
ere collected with a PANalytical Empyrean X-ray diffractometer
quipped with a Cu-K monochromatic radiation source. The scan-
ing angle ranged from 2 to 60◦ in 2 steps of 0.26◦ and a counting
ime of 5 s/step.
.2.6.2. Scanning electron microscopy. The surface morphology of
M, KN and FD PDs were observed by scanning electron microscopy
SEM) on a FEI Quanta 400 FEG SEM from FEI (Hillsboro, OR, USA).
he powder samples were also observed were mounted onto a
etal stubs and vacuum-coated with a layer of gold/palladium
rior observation in microscope.
.2.6.3. Fourier transformed-infrared spectroscopy (FT-IR). FT-IR
pectroscopy was  used to investigate the physicochemical inter-
ctions occurring PM,  KN and FD PDs. The IR spectra were obtained
sing the PerkinElmer® (Spectrum 400) equipped with an atten-
ated total reﬂectance (ATR) device and zinc selenite crystals. The
amples were transferred directly to the ATR compartment, and the
esult was obtained by combining the 16 scans. The spectra were
ecorded between 4000 and 600 cm−1 with a resolution of 4 cm−1.
.2.6.4. In vitro drug release. The in vitro dissolution proﬁles of DAP,
Ms and PDs were conducted using the USP paddle apparatus for all
he samples. The samples were dropped into 900 mL  of phosphate
uffer pH 6.8 maintained at a temperature of 37 ◦C ± 0.5 ◦C and
tirred at a speed of 100 rpm for 60 min. A 5 mL  aliquot of the sam-
le was withdrawn at 5, 10, 15, 30, 45, 60 min  and further replaced
ith same volume of dissolution medium kept at the same temper-
ture. Samples were ﬁltered and analyzed by spectrophotometry at
91 nm.
The release proﬁles were assessed by calculating the similarity
actor f2 for each sample pair, according to the Eq. (2) [24,25]:
 2 = 50 × log
⎧⎪⎨
⎪⎩
⎡
⎣1 +
(
1
n
) n∑
j=1
|Rj − Tj|
2
⎤
⎦
5
× 100
⎫⎪⎬
⎪⎭
(2)
here n is the number of dissolution points, Rj and Tj are the refer-
nce and test dissolution values at time t. Two dissolution proﬁles
re considered similar when the f2 value is 50–100 [26].
. Results and discussion
.1. Equilibrium solubility of DAP in different pH
The values of DAP solubility determined at different pH, are
resent in Fig. 1. The observed behavior of solubility dependence on
H was due to the chemical characteristics of DAP, and the presence
f amino groupings. At lower pH (1.2), the major micro-species of
he drug is with both amino group protonated, which increase the
olubility of the drug. On the other hand, as the pH increases, the
olubility decreases, once at pH 4.5, 6.8 and 7.4 the drug maintain
ts molecular structure.
Moreover, it was observed that at physiological temperature
37 ◦C) the solubility was almost two fold higher.Fig. 1. Effect of temperature and pH on the solubility of DAP (n = 3).
Drug permeation occur mainly in the small intestine, and
depends on several physiological and physical–chemical param-
eters concerning pharmaceutical dosage [27]
Despite the high protonation of DAP at lower pH leading to its
high solubility, the luminal pH of the small intestine, where the
majority of the drug is absorbed, ranges between 5.5 and 7.0. At
these range of pH DAP molecule is almost totally unionized (pKa
2.41) which may  lead to recrystallization in the lumen, hindering
permeation rate [28].
3.2. Screening of different carrier
Various carriers were used to evaluate the enhancement of DAP
solubility, in two different ratios, in order to observe the tendency
of DAP solubility with the amount of the carriers. The equilibrium
solubilities of the different DAP PMs  in ultra-pure water are shown
in Fig. 2.
Due to the hydrophobic characteristics of Gelucire 44/14 and
Compritol ATO 888, it was expected that DAP solubility would not
increase merely by preparing PM.  These type of carriers are non-
swellable lipophilic material, presenting a surface activity of self-
emulsifying properties. Thus it is necessary to ﬁrst melt the carriers
and then disperse drug. Generally, hydrophobic carriers tend to
promote sustain the release of the drug [29,30], which is not the
purpose of this work.
The PM with carbohydrates carriers (inulin and chitosan) did
not show great potential in the increment of solubility of theFig. 2. Effect of different carriers on the equilibrium solubility of DAP in water at
37 ◦C (n = 3).
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Table  2
Equilibrium solubility obtained from physical mixtures (PM), and PDs obtained by kneading (KN) and freeze-drying (FD).
Sample Independent variable Dependent variables
X1 X2 Physical mixture (PM) (g/mL) Kneading (KN) (g/mL) Freeze Dried (FD) (g/mL)
Real (mg) Coded Real (mg) Coded
1 200 −1 0 −1 150.2 ± 7.9 252.3 ± 11.5 408.5 ± 22.6
2  200 −1 8 0 144.2 ± 10.8 198.2 ± 4.9 344.2 ± 22.0
3  200 −1 20 +1 134.7 ± 55.8 198.3 ± 7.8 353.1 ± 21.7
4  600 0 0 −1 166.2 ± 10.5 315.6 ± 5.8 502.4 ± 18.2
5  600 0 8 0 172.4 ± 16.5 249.7 ± 3.5 380.0 ± 30.1
6  600 0 20 +1 100.9 ± 10.3 253.0 ± 12.5 355.1 ± 21.0
7  1000 +1 0 −1 189.8 ± 8.1 459.7 ± 4.4 994.6 ± 47.7
8  1000 +1 8 0 192.7 ± 11.2 399.4 ± 9.8 835.0 ± 22.8
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 The sample highlighted in bold showed the best results.
roportional to the amount of polymer used. On the other hand,
PMC provided a slight decrease on DAP solubility inversely pro-
ortional to the amount of polymer, probably due its gelling
roperties, leading to drug entrapment. Moreover, PEGs did not
emonstrate any positive effect on DAP solubility, and a positive
orrelation between the concentration of PEG and the molecular
eight was observed on DAP solubility. Despite the extensive use of
EGs in PDS, the decrease in DAP solubility in PM suggests that the
nteraction between the drug and the polymer should be studied
eeper.
The use of PVP K30 to formulate PDs was previously proposed
16,18,31–33]. The mechanism by which it leads to increased equi-
ibrium solubility is due to wetting and decreased surface tension
ffects [32,33]. In addition, due to the amorphous characteristic of
VP, the system became partially crystalline, which is more favor-
ble to be completely amorphous when formulating PDs, where the
rug has a better chance to be molecularly dispersed in the carrier
29], especially when there is a possibility of hydrogen interactions
etween the carrier and the drug [30].
Based on the results, the PVP K30 was the polymer that seems
o be most suitable to increase DAP solubility, which solubil-
ty increases as the amount of PVP increases. It is expected that
pplying different processes to obtain PDs, better results may  be
chieved. Therefore, PVP K30 was chosen as polymer model for
urther studies.
Recent studies have shown that during the accelerated dis-
olution of binary PDs, an unavoidable supersaturation of drug
nd its consequent recrystallization may  occur. In this context,
he properties of the carrier can be tailored to the needs of the
ystem, e.g., stabilization of a solid solution or improvement of
he dissolution rate [34]. The inclusion of surfactants as a third
omponent in the PDs may  help to avoid drug recrystallization
nd to stabilize the systems [35,36]. It was already reported that
®he use of Pluronic may  maintain solution concentrations that
ere higher than the equilibrium solubility of crystalline drug
ue to solubilizing effect and surface activity of these polymeric
urfactants [20].
able 3
egression analysis for responses for physical mixtures (PM), and PDs obtained by knead
Reg. coefﬁcients PM p-Value KN 
Intercept. 213.225 – 446
X1 (L) −0.378 0.0521 −0
X1 (Q) 0.0006 0.0090 0
X2 (L) −2.299 0.5904 −18
X2 (Q) −0.258 0.2095 0
X1·X2 0.002 0.4872 −0
R2 0.989 
Fcalculated 56.63 
 Numbers highlighted in bold are the p < 0.05.329.1 ± 9.0 515.4 ± 48.5
3.3. Optimization and evaluation of PDs by design of experiments
and response surface methodology
RSM is a collection of mathematical and statistical techniques
based on the ﬁt of a polynomial equation to the experimental
data, which must describe the behavior of a data set with the
objective of making statistical previsions. Before applying the RSM
methodology, it is ﬁrst necessary to choose an experimental design
that will deﬁne which experiments should be carried out in the
experimental region being studied [37]. DoE, on the other hand,
is an optimization technique that aims to evaluate all the poten-
tial factors simultaneously, systematically and speedily, and can
be applied for process or products [38]. Together they are useful
tools during formulation design, and has been applied successfully
during the optimization of PDs [16,18,20,39,40].
In order to promote further solubility of DAP, a novel ternary PDs
system consisting of DAP, PVP and Pluronic F68 were investigated
through DoE. PDs systems were obtained by kneading (KN) and
freeze drying (FD) methods, in order to evaluate the inﬂuence of
the process.
The experimental results with the respective observed
responses of the dependent variables are shown in Table 2. The
maximum equilibrium solubility after 48 h varied between 100.9
and 192.7 g/mL for PM,  from 198.2 and 459.7 g/mL for KN and
from 344.2 and 994.6 for FD solid dispersion. The highest value of
equilibrium solubility was obtained from the sample 7 of the FD PD,
being also the formulation that originated higher solubility values
using KN. All the values obtained from FD solid dispersions were
higher than those obtained from KD, proving that this method was
more efﬁcient in the improvement of DAP solubility. Likewise, in
all the cases, the inﬂuence of the Pluronic F68 as a third compo-
nent of solid dispersions was  not positive, according to the results
of equilibrium solubility.Based on these results, the process inputs and the response
variables were related using a quadratic equation with statistical
analysis through STATISTICA 10 software. X1 represent amount of
PVP K30 and X2 represent the amount of Pluronic F68. The results of
ing (KN) and freeze-drying (FD).
p-Value FD p-Value
.254 – 692.565 –
.878 0.0770 −1.844 0.0028
.0016 0.0099 0.004 0.0002
.230 0.1808 −10.551 0.1983
.786 0.1753 0.438 0.2050
.006 0.4682 −0.0207 0.0198
0.989 0.999
408.67 3287.90
666 L.L. Chaves et al. / International Journal of Biological Macromolecules 81 (2015) 662–671
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mig. 3. Response surface plot showing the effect of the amount of PVP K30 and P
btained  by kneading (KN) and freeze-drying (FD).
he regression coefﬁcients of the obtained equations, the R squares
alculated and the Fcalculated for each model are shown in Table 3.
s observed, all the F calculated were much higher than the Fcritic
9.02) with 95% of conﬁdence, proving that the models are sta-
istical signiﬁcant, and could be used to achieve a suitable input
alues. The larger the coefﬁcient is, the higher is the inﬂuence
f the material attribute on the response. It can be inferred from
able 3 that the PVP K30 as material attribute have a signiﬁcant
ffect on the equilibrium solubility of DAP in all the techniques
sed.
With the equations obtained, 3D responses surface plots were
btained, as shown in Fig. 3. The RSM models shows correlations
oefﬁcient (R2) of 0.989 for PM,  0.989 for KN and 0.999 for FD
ethod, which prove that the models obtained are very well cor-
elated. The qualities of the models were evaluated by plotting
orrelation plots (predicted data vs experimental data) and resid-
al plots (residual vs experimental data) (Fig. 4). It could be seen
hat all the models show high predictability coefﬁcients, with few
utliers, mainly for FD process, thus the predicted values for the
hree models were reasonably similar to the experimental data. In
ddition, the residual plots provided a better visual comprehen-
ion of the capability of the models, since all the data were widely
cattered in predicting DAP solubility, as all of the points are tightly
istributed along the horizontal axis (Fig. 4b, d and f). Thus, they can
e judged as suitable models, with no trend in the data. These data
eﬂect greater robustness in the freeze-drying process, since all the
rocess parameters may  be controlled, which is of great value to
he scale-up stage.
The inﬂuence of the amount of PVP K30 in the FD process was
ore relevant, comparing to KN and PM,  conﬁrmed by the valuesc F68 on the equilibrium solubility of DAP from physical mixtures (PM), and PDs
of the intercept of the equations obtained, which are the arithmetic
means responses of all the runs [39], i.e.,  in all the FD PDs, the equi-
librium solubility was higher than the others. In addition, for all
the processes the quadratic coefﬁcient had positive effect on the
responses, indicating that the effect of the PVP on the equilibrium
solubility is more important at higher amounts. On the other hand,
the linear term of the amount of PVP had a negative impact for the
freeze drying process. It can be explained by the fact that the freeze
drying process itself is able to improve DAP solubility, and small
amount of PVP would not inﬂuence on the response, and even lead
to a decrease on the ﬁnal result, only being advantageous if used in
higher concentrations.
Moreover the amount of Pluronic F68 inﬂuenced negatively,
i.e., decreased the positive effect of PVP K30, once the regression
coefﬁcient of X1.X2 was also relevant, but with negative signal. It
was expected that the addition of a surfactant may increase the
equilibrium solubility of DAP, as already described in other stud-
ies. Although, due to the amphiphilic structure of Pluronic F68,
which has the properties to self-assemble into micelles in aqueous
solution when the concentration was above the critical micellar
concentration, DAP might be entrapped by micelles formed, which
may become an obstacle to the further solubilization after the 48 h
[34]. Thus, for further characterization, sample 7 of the FD PD was
chosen.3.4. Solid dispersions characterization
For the characterization of the solid dispersions, sample 7 was
selected, according to the results of the formulation optimization.
L.L. Chaves et al. / International Journal of Biological Macromolecules 81 (2015) 662–671 667
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.4.1. X-ray diffraction
The XRD patterns of PDs indicate changes in its crystalline struc-
ure. The diffractograms of DAP, PVP K30, and PDs obtaining by
neading and freeze drying method are depicted in Fig. 5. The
rystalline character of DAP is explicit in the XRD, reﬂected in the
ntense peaks between 10◦ and 30◦ [9], while the PVP K30 is com-
letely amorphous, with complete absence of peaks. Regarding the
Ds, it could be seen that the kneading method did not gener-
te a completely amorphous material, although the intensity and
ome peaks is decreased, and in some cases, disappeared. On the
ther hand, in the freeze dried PDs XRD patterns, it was  not found
ny characteristic peak of DAP, which indicates that the material
s completely amorphous, due to a strong intermolecular interac-
ion between the drug and the polymer, better explained in the
urther characterization, and due to the inﬂuence of the lyophiliza-
ion process itself, already described in the literature, responsible
o produce amorphous material, with very low density [32].
Fig. 5. X-ray diffractograms of dapsone (DAP) and PVP K30 raw material; physicalained by RSM where: a and b are from PM,  b and c are from KN, e and f are from FD.
3.4.2. Scanning electron microscopy
Fig. 6 shows SEM images of DAP, PVP K30, PM,  and PDs obtained
by kneading and freeze dried process. The crystalline proﬁle of DAP
and the amorphous character of PVP K30, with rounded shapes,
are well deﬁned. In the SEM images of PM,  the drug interacts only
superﬁcially, while in the images obtained from KN PD, the par-
ticles present new shapes, not spherical, where the drug appear
to be inserted in the polymeric matrix, in its crystalline form. This
phenomenon is able to improve the drug solubility due to a higher
interaction between the drug and the PVP K30, leading to a decrease
of the superﬁcial tension.
In the case of the FD PD, the images show irregular particles
with ﬂake-like appearance, which is typical of freeze-dried mate-
rials [32,41]. In these images it was not possible to identify the
crystals of DAP neither the rounded shapes of PVP K30. Instead, a
homogeneous distribution was observed, wherein the drug appears
to be dispersed within the polymer. This homogeneous matrix
 mixtures (PM), and PDs obtained by kneading (KN) and freeze-drying (FD).
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big. 6. Representative scanning electron microscope (SEM) images of PVP K30 (a),
KN)  (e, f), and freeze-drying (FD) (g, h).
eﬂects the best results obtained during the formulation optimiza-
ion, once in this case the interaction between the drug and the
olymer was at molecular level, which facilitate the dissolution
rocess..4.3. Fourier transformed-infrared spectroscopy (FT-IR)
In the FT-IR spectra from DAP (Fig. 7), it can be observed a
and at 3300–3400 cm−1 corresponding to the stretch of theAP raw material (b); physical mixtures (PM) (c, d), and PDs obtained by kneading
amine group (N H), and peaks corresponding to bend vibration
of NH2 groups between 1590 and 1550 cm−1. The bands at 1143
and 1180 cm−1 are ascribed to the symmetric and asymmetric
vibrations of the sulfone group ( SO2) [42]. PVP contains an amide
carbonyl on the pyrrolidone monomer, which is a strong hydrogen
bond acceptor [43]. The C O group of PVP is considered to be the
most favorable site for interaction due to the steric constraints on
the N atom [44]. The spectra of the PVP starting material showed,
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Pig. 7. FT-IR spectra (a) and detailed N H stretching region (3700–3000 cm−1) (b) 
mong others, important bands at 2955 cm−1 (C H stretch) and
665 cm−1 (C O) [32].
Regarding the PDs, compared to the PM,  it could be seen that the
egion corresponding to the N H bonding showed a lower inten-
ity and hypochromic shift, especially in the case of FD, which
an be explained by hydrogen bond between the drug and PVP
30 at a molecular level. Moreover, the broadening of the stretch-
ng region could be attributed to changes in the crystal structure,
article shape and size [45]. Intermolecular interactions in the
morphous solids can directly affect their molecular mobility [46]
ausing changes in the oscillating dipole of the molecules, which
ay  lead to changes in the frequency and bandwidth of interacting
roups in the spectrum [47]. Thus, drug–polymer interactions in
Ds can be explored using IR spectroscopy, whereby the presence
f speciﬁc interactions is often used to infer miscibility. Speciﬁc
nteractions between the drug and polymer are usually hydro-
en bonding [48]. Additionally, amorphous systems may  involve
 weakening or strengthening of hydrogen bonds thus leading to
ecrease in band intensities, due to the general diffusion and broad-
ning [46].
DAP molecule contains considerable potential moieties for
ntermolecular interactions via NH2 and SO2 functional groups
46,7]. The SO2 group has a strong electron withdrawing nature,
lthough this phenomenon may  loses its electron-accepting capa-
ility due to the presence of aromatic ring directly bonded, which
ead to a stabilization of its electrons at the neighborhood. On the
ther hand, the NH2 group becomes much more susceptible to
onate protons, which is probably the most available site for hydro-
en bonding.
.4.4. In vitro drug release
The release proﬁles of DAP from PDs in comparison with DAP
owders and PMs  is depicted in Fig. 8. DAP powder exhibited
 poor dissolution rate with 41% of drug dissolved after 30 min.
M presented a slight improvement in the dissolution properties
n comparison with the pure drug. These results suggested that
VP itself might act as a weak solubilizer in PMs, contributing to
he limited increase in drug dissolution, as well as in preventing
rug aggregation [34]. Nevertheless, it was evident that PDs exhib-
ted faster dissolution rates than DAP powders and corresponding
Ms. The drug release from PD formulations were considerably
ncreased, indicating a fast and burst release of DAP in dissolution
edia, since more than 75% of drug was released in ﬁrst 10 min,
hen compared to the pure drug, which dissolution was very slow,
ess than 10% in the same period.
The dissolution rate improvement of the drug in the PDs may
e attributed to the high hydrophilicity of the PVP, smaller particle
ize and consequently larger surface area (especially in freeze-dried
Ds) and decreasing in drug crystallinity [33,45].Fig. 8. Dissolution proﬁles of dapsone (DAP) raw material, physical mixtures, and
PDSs obtained by kneading (KN) and freeze-drying (FD) processes, and the similarity
factors between all the formulations and pure drug.
The similarity factor, f2 has been used by the FDA for the com-
parison of dissolution proﬁles. f2 values between 50 and 100 to
indicates similarity between two dissolution proﬁles and f2 values
of 100 for two identical proﬁles [25]. From the results, none simi-
larity was observed between the dissolution proﬁles of pure drug,
PM and both PDs formulation, since all the correlations provided
f2 values below 50 (Fig. 8). This corroborates with the morpho-
logical and crystallinity differences observed within FD and KN
samples. Despite the burst effect in the drug release proﬁle, the
dissolution in the ﬁrst 10 min was  faster for FD dispersions com-
pared with the KN samples. This phenomenon may  be attributed
to the very wettable and needle shaped particles, in addition to a
completely amorphous powder obtained by freeze drying method,
which not can be obtained from the kneading process, from which
was obtained a partially crystalline powder, as observed from the
XRD and SEM analysis. Accordingly, the particle size and particle
shape of the PDs powders may  be considered as the main cause
of the drug release rate enhancement, since in all formulations the
amount of PVP was  the same, so its hydrophilic character did not
interfere for differentiate the proﬁles [32,45].
Despite the freeze-drying process has improved DAP solubility
and immediately released the drug, and the fact that this process
can be easily scale-up with low losses, the kneading process also
provided satisfactory results considering the simplicity low-cost of
the technique.4. Conclusion
In this study, QbD was  successfully applied for pharmaceuti-
cal development of DAP PDs, through the application of DoE and
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SM as tools. A full-factorial design was developed to investigate
he effect of the variables (amount of PVP K30 and amount of
luronic® F68) on the equilibrium solubility of the PM,  KN and FD
Ds. Implementation of response surface plot and regression corre-
ation analysis revealed the relationship between the variables and
he responses. It was observed that the solubility of DAP increased
irectly with the increase in amount of PVP K30, which was not
bserved with the addition of Pluronic® F68. This phenomenon was
ore evident for the formulations obtained by the freeze-drying
ethod. These ﬁndings could be explained by the improved wett-
bility caused by the highly hydrophilic polymer PVP, mainly by
article size reduction, by the conversion of the crystalline form to
he amorphous form and by the molecular interactions between
rug and polymer in resultant dispersions, as supported by the
T-IR spectra.
Results show that the PDs preparation method had a signif-
cant effect on the dissolution performance of DAP. Of the two
rocesses studied, freeze-drying was more effective in produc-
ng PDs with higher dissolution rates than kneading. Although,
espite the substantial differences between them from a manu-
acturing perspective, both of the solvent evaporation techniques
sed were able to improve DAP solubility and immediately released
he drug. Freeze-drying can be advantageous in terms of dissolu-
ion enhancement but the associated production costs should be
onsidered before applying this technology.
The combination of preliminary studies and experimental
esign performed in the present study together with image and
pectral analysis represent one step toward DAP PDs formula-
ion development on the basis of quality by design, and showed
ncreased prediction efﬁciency during the optimization procedure.
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